INNT
TOTAL INVALIDATION PROCESSED BY THE IB
11/07/2025
Voltar para busca
Dado oficial do USPTO
OPHTHA FUTUR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
12/07/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 42
Data de depósito
01/09/2016
Data de registro
09/01/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/07/2024
Última transação
12/07/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
DE
Examinador
PARKS, KIMBERLY
Unidade examinadora
M30
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "OPHTHA" in green with a green curved band over the letter "O", followed by the wording "FUTUR" in black.
Titulares e representantes
Titulares
Pharmpur GmbH
Representantes
Paul D. Bianco Fleit Gibbons Gutman Bongini & Bianco PL
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicinein particular ophthalmologic preparations; ocular pharmaceuticalspharmaceuticals to support ophthalmic surgery
Classe 10
Surgicalmedicaldental and veterinary apparatus and instruments for use in ophthalmic treatment and ophthalmic surgerycataract removal equipmentvitrectomy equipment and endoscopes; artificial limbs; artificial eyes; artificial teeth; orthopedic articlessilicone orthopedic devices for therapeutic usesilicone orthopedic implantspillows and compression pads for orthopedic useelastic bandages and plaster bandages for orthopedic purposessynthetic supportive bandages and orthopedic support bandages; suture materials
Classe 42
Scientific and technological servicesscientific researchanalysistestingquality management building and product developmentin the field of treatment of eye diseases and ophthalmic surgery; research relating to technologyin particular chemical technological research; advisory services relating to technological research in the field of chemicalphysicalbiological and technological research for the development of ophthalmic drugs and medical devices; provision of information relating to technological research in the field of ophthalmic pharmaceuticalsmaterials and medical devices used in ophthalmology; technological services in the field of ophthalmologytechnological consultationtechnological informationproduct developmentdevelopment of manufacturing equipment used for ophthalmic drugs and products and advisory in the field of site planning for manufacturing of ophthalmic devices; chemical research; chemical research and analysis services; research on the subject of pharmaceuticals; pharmaceutical drug development services; pharmaceutical research and development; medical and pharmaceutical research and development; consultancy pertaining to pharmacologyin particular ophthalmology; conducting clinical trials for pharmaceutical products; product evaluations and product registrationreports and post market follow up of ophthalmic products in international marketsevaluations of scientific projects related to the ophthalmic industry services for assessing the efficiency of pharmaceuticalsplanning and management of quality relevant activities in the field of ophthalmic manufacturing; research and development for the pharmaceutical industry; providing information about the results of clinical trials for pharmaceutical products; information technology consultancy services for the pharmaceutical and healthcare industries; all aforementioned services particularly relating to ophthalmology and ophthalmologic preparations
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
24/06/2025
INPC
INVALIDATION PROCESSED
24/06/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
26/03/2025
C71T
CANCELLED SECTION 71
26/07/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
09/01/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/10/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/06/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/04/2018
FIMP
FINAL DISPOSITION PROCESSED
17/04/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/04/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
09/01/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/10/2017
PUBO
PUBLISHED FOR OPPOSITION
24/10/2017
GPNX
NOTIFICATION PROCESSED BY IB
21/10/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/10/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/10/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/10/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/09/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/09/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/09/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/09/2017
RFNT
REFUSAL PROCESSED BY IB
25/03/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/03/2017
RFRR
REFUSAL PROCESSED BY MPU
07/03/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/03/2017
CNRT
NON-FINAL ACTION WRITTEN
06/03/2017
MAFR
APPLICATION FILING RECEIPT MAILED
28/02/2017
DOCK
ASSIGNED TO EXAMINER
24/02/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/02/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/02/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OPHTHA FUTUR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.